Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Taysha Gene Therapies, Inc. (TSHA)

Taysha Q2 2026 net loss widens to $46.6 million as R&D spending rises

Negative Impact 3 of 5 earnings Written later

Taysha Gene Therapies reported a second-quarter 2026 net loss of $46.6 million, or $0.13 per share, up from $26.9 million, or $0.09 per share, a year earlier. The company recorded no revenue in the quarter, compared with $2.0 million in the same period of 2025, and cited higher research and development costs tied to manufacturing and clinical trials for its lead Rett syndrome therapy, TSHA-102.

Key points

  • Net loss was $46.6 million, or $0.13 per share, for the three months ended June 30, 2026, versus $26.9 million, or $0.09 per share, a year earlier.
  • Research and development expenses were $38.6 million, up from $20.1 million, mainly from BLA-enabling PPQ manufacturing and clinical trial costs.
  • Revenue was zero in the quarter, compared with $2.0 million in the second quarter of 2025.
  • Cash and cash equivalents were $455.4 million at June 30, 2026, including $230.0 million in gross proceeds from a June 2026 follow-on offering; the company expects cash to last into the second half of 2028.

The filing

CompanyTaysha Gene Therapies, Inc. (TSHA)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:05 PM ET
Accession number0001193125-26-344594

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.